Maksym Galkin received his Master's degree in Biochemistry from Kyiv National University in 2014. After that, he worked at the Department of Neurochemistry at the Palladin Institute of Biochemistry. He received his PhD degree from Charles University (Prague, Czech Republic), where he defended his dissertation on the development of a method for testing selective inhibitors of alpha-synuclein aggregation, a protein that plays a key role in the development of Parkinson's disease.